MA49704A - Dérivés d'acide biliaire à marquage isotopique - Google Patents
Dérivés d'acide biliaire à marquage isotopiqueInfo
- Publication number
- MA49704A MA49704A MA049704A MA49704A MA49704A MA 49704 A MA49704 A MA 49704A MA 049704 A MA049704 A MA 049704A MA 49704 A MA49704 A MA 49704A MA 49704 A MA49704 A MA 49704A
- Authority
- MA
- Morocco
- Prior art keywords
- isotopic
- labeled
- acid derivatives
- biliary acid
- biliary
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J17/005—Glycosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762536326P | 2017-07-24 | 2017-07-24 | |
| US201762536609P | 2017-07-25 | 2017-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49704A true MA49704A (fr) | 2021-03-31 |
Family
ID=65041285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049704A MA49704A (fr) | 2017-07-24 | 2018-07-23 | Dérivés d'acide biliaire à marquage isotopique |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11472831B2 (fr) |
| EP (1) | EP3658150A4 (fr) |
| JP (1) | JP2020528892A (fr) |
| KR (1) | KR20200031145A (fr) |
| CN (1) | CN111050772A (fr) |
| AU (1) | AU2018307611A1 (fr) |
| BR (1) | BR112020001362A2 (fr) |
| CA (1) | CA3070837A1 (fr) |
| IL (1) | IL272119A (fr) |
| MA (1) | MA49704A (fr) |
| MX (1) | MX2020000873A (fr) |
| WO (1) | WO2019023103A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202021595A (zh) | 2018-08-10 | 2020-06-16 | 德商菲尼克斯製藥股份有限公司 | 用於預防及治療困難梭狀芽孢桿菌關聯疾病之異石膽酸或異別石膽酸及其氘化衍生物 |
| EP4011899A4 (fr) * | 2019-08-06 | 2022-09-28 | Huang, Qiang | Composés d'acide désoxycholique, compositions pharmaceutiques et leurs utilisations |
| CN112898369B (zh) * | 2019-12-04 | 2024-09-17 | 博瑞生物医药（苏州）股份有限公司 | 用于制备奥贝胆酸的方法 |
| JPWO2023038093A1 (fr) * | 2021-09-09 | 2023-03-16 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10113257C1 (de) | 2001-03-19 | 2002-11-14 | Inst Mikrotechnik Mainz Gmbh | Elektrophoresevorrichtung und ihre Verwendung |
| WO2008002573A2 (fr) | 2006-06-27 | 2008-01-03 | Intercept Pharmaceuticals, Inc. | Dérivés de l'acide biliaire en tant que des ligands de fxr pour la prévention ou le traitement de maladies ou conditions médiées par le fxr |
| PL2376519T3 (pl) | 2008-11-19 | 2014-04-30 | Intercept Pharmaceuticals Inc | Modulatory TGR5 i sposoby ich zastosowania |
| AU2013277429B2 (en) | 2012-06-19 | 2016-01-14 | Intercept Pharmaceuticals, Inc. | Preparation, uses and solid forms of obeticholic acid |
| BR112015009395A2 (pt) | 2012-10-26 | 2017-07-04 | Intercept Pharmaceuticals Inc | processo para preparação de derivados do ácido biliar |
| BR112015028399B1 (pt) | 2013-05-14 | 2021-11-16 | Intercept Pharmaceuticals, Inc | Derivados 11-hidroxila de ácidos biliares e conjugados de aminoácido dos mesmos como moduladores de receptor farnesoide x, composição farmacêutica e uso dos referidos derivados |
| US20150112089A1 (en) | 2013-10-22 | 2015-04-23 | Metselex, Inc. | Deuterated bile acids |
| CN105985396A (zh) | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| WO2016168553A1 (fr) | 2015-04-17 | 2016-10-20 | Concert Pharmaceuticals, Inc. | Acide obéticholique deutéré |
| PE20180690A1 (es) * | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| EP3981779A1 (fr) | 2015-10-07 | 2022-04-13 | Intercept Pharmaceuticals, Inc. | Modulateurs du récepteur farnésoïde x |
| WO2017147159A1 (fr) * | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Dérivés d'acide biliaire utilisés deutérés utilisés comme agonistes de fxr/tgr5 et leurs méthodes d'utilisation |
| CN109467585A (zh) * | 2016-03-11 | 2019-03-15 | 深圳市塔吉瑞生物医药有限公司 | 用于预防或治疗fxr-介导疾病的胆烷酸化合物 |
-
2018
- 2018-07-23 AU AU2018307611A patent/AU2018307611A1/en not_active Abandoned
- 2018-07-23 JP JP2020503292A patent/JP2020528892A/ja active Pending
- 2018-07-23 CA CA3070837A patent/CA3070837A1/fr not_active Abandoned
- 2018-07-23 BR BR112020001362-5A patent/BR112020001362A2/pt not_active Application Discontinuation
- 2018-07-23 CN CN201880054875.6A patent/CN111050772A/zh active Pending
- 2018-07-23 MA MA049704A patent/MA49704A/fr unknown
- 2018-07-23 US US16/632,093 patent/US11472831B2/en active Active
- 2018-07-23 EP EP18838551.2A patent/EP3658150A4/fr not_active Withdrawn
- 2018-07-23 WO PCT/US2018/043239 patent/WO2019023103A1/fr unknown
- 2018-07-23 KR KR1020207004777A patent/KR20200031145A/ko unknown
- 2018-07-23 MX MX2020000873A patent/MX2020000873A/es unknown
-
2020
- 2020-01-19 IL IL272119A patent/IL272119A/en unknown
-
2022
- 2022-09-07 US US17/939,326 patent/US20230057232A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL272119A (en) | 2020-03-31 |
| CN111050772A (zh) | 2020-04-21 |
| JP2020528892A (ja) | 2020-10-01 |
| US20200165290A1 (en) | 2020-05-28 |
| AU2018307611A1 (en) | 2020-02-06 |
| KR20200031145A (ko) | 2020-03-23 |
| EP3658150A1 (fr) | 2020-06-03 |
| US20230057232A1 (en) | 2023-02-23 |
| BR112020001362A2 (pt) | 2020-08-11 |
| EP3658150A4 (fr) | 2021-03-31 |
| US11472831B2 (en) | 2022-10-18 |
| MX2020000873A (es) | 2020-07-22 |
| CA3070837A1 (fr) | 2019-01-31 |
| WO2019023103A1 (fr) | 2019-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49421A (fr) | Formulations d'arn | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA42615A (fr) | Composés phosphodiamide antiviraux d'ester d'acide bêta-aminé | |
| MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| MA51429A (fr) | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase | |
| MA42038A (fr) | Dérivés de cyclohexane à substitution amido | |
| MA49704A (fr) | Dérivés d'acide biliaire à marquage isotopique | |
| MA54521A (fr) | Dérivés d'oxopyridine substitués | |
| MA51431A (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| DK3924443T3 (da) | Compositions | |
| MA45478A (fr) | Compositions de conjugués d'acides nucléiques ciblés | |
| MA52877A (fr) | Acide hyaluronique stabilisé | |
| MA46567A (fr) | Formes cristallines de l'éravacycline | |
| DK3506901T3 (da) | Anvendelse af kynurensyre til behandling af muskelatrofi | |
| MA50439A (fr) | Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3 | |
| DK3512518T3 (da) | Buprenophinformuleringer med langvarig frigivelse | |
| MA45451A (fr) | Formulations tensioactives destinées à l'inhalation | |
| MA50575A (fr) | Préparation d'acide phosphorique | |
| MA42048A (fr) | Dérivés d'aminoesters | |
| MA56504A (fr) | Dérivés de pyridin-3-yle | |
| DK3911298T3 (da) | Formuleringer | |
| DK3908321T3 (da) | Farmaceutisk sammensætning | |
| MA49761A (fr) | Dérivés d'acide glycyrrhétinique de traitement de l'hyperkaliémie | |
| FR3036284B1 (fr) | Acide lipoique en tant qu'agent osmoprotecteur |